Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Treatments

Topic: Risk, prevention and care in population studies

Plain-language summary

Background Pimavanserin is approved by the US Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease. We analyzed the effect of pimavanserin on psychosis in patients with Lewy body dementia, including Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), from the phase 3 HARMONY trial. Methods This subgroup analysis included patients with PDD or DLB from HARMONY, a previously completed, multicenter, randomized, discontinuation study of pimavanserin for dementia-related psychosis. Patients with moderate to severe psychosis received pimavanserin 34 mg once daily for 12 weeks (open-label treatment). Those who achieved a sustained response at weeks 8 and 12 were randomized to continue treatment with pimavanserin or discontinue treatment and receive placebo for up to 26 weeks in the double-blind period. The primary endpoint was the time to psychosis relapse as defined by prespecified criteria. Safety was evaluated by adverse events; effects on motor symptoms and cognitive abilities were also assessed. Results Overall, 392 patients were enrolled in HARMONY; 49 patients with PDD and 27 patients with DLB were included in the open-label safety analysis, of whom 46 met response criteria and were randomized to receive pimavanserin (n = 22) or placebo (n = 24) during the double-blind period. Psychosis relapse risk was significantly lower with pimavanserin vs. placebo (hazard ratio, 0.031; 95% CI, 0.010-0.103; 2-sided nominal P Conclusions Psychosis relapse risk was significantly lower with pimavanserin vs. placebo in patients with Lewy body dementia. Pimavanserin was also well tolerated and did not worsen motor or cognitive function. Results should be interpreted cautiously since this study is a post hoc analysis of a previous trial that was not originally designed or powered to draw clinical conclusions based on dementia subgroups. Trial registration ClinicalTrials.gov Identifier: NCT03325556 (registered 18 October 2017).

What this study adds

Evidence grade: Early

The record lists 76 participants. In this subgroup analysis of the HARMONY trial, pimavanserin was associated with a significantly lower risk of psychosis relapse in patients with Lewy body dementia. Reported effect size: Psychosis relapse HR 0.031 (95% CI 0.010-0.103) vs placebo among 46 randomised responders.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Torres-Yaghi, Y., Chrones, L., Abler, V., & Brunson, G. (2025). Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study. BMC Neurology. https://doi.org/10.1186/s12883-025-04496-8

Vancouver

Torres-Yaghi Y, Chrones L, Abler V, Brunson G. Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study. BMC Neurology. 2025. doi:10.1186/s12883-025-04496-8. PMID: 41286676.

BibTeX

@article{torresyaghi2025-41286676,
  author  = {Torres-Yaghi, Y. and Chrones, L. and Abler, V. and Brunson, G.},
  title   = {{Safety and efficacy of pimavanserin in patients with Lewy body dementia experiencing dementia-related psychosis in the HARMONY study}},
  journal = {BMC Neurology},
  year    = {2025},
  doi     = {10.1186/s12883-025-04496-8},
  pmid    = {41286676},
  url     = {https://doi.org/10.1186/s12883-025-04496-8}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

In this subgroup analysis of the HARMONY trial, pimavanserin was associated with a significantly lower risk of psychosis relapse in patients with Lewy body dementia. The analysis included a small number of patients with Parkinson's disease dementia or dementia with Lewy bodies.

Study details

Limitations

Post hoc subgroup analysis not powered for these dementia types; only 46 randomised; enriched design (only responders randomised) inflates apparent effect; industry-sponsored; pimavanserin carries a boxed warning for mortality in dementia-related psychosis.

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 1 of 4; Study design 11 of 12; Strength of evidence 2 of 5; Peer-review validation 10 of 10; How recent 4 of 5; Sample size 1 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 1 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 0 of 3; Multicenter collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 46 of the 94 points it could be judged on, which is 49 of 100. Total 49 of 100.46 of the 94 points we could judge = 49 of 100

Published in a peer-reviewed journal, and it is a large phase 3 trial. We have no data on senior author's track record and free to read, so those were left out: it earned 46 of the 94 points we could judge it on, which is 49 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (BMC Neurology)
Journal's citation record 1 / 4 BMC Neurology: journal h-index 122 (OpenAlex, 2026-10-29)
Study design 11 / 12 A large phase 3 trial
Strength of evidence 2 / 5 Rated “early” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 4 / 5 2025 — within 3 year(s) of the newest study here
Sample size 1 / 4 76 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 1 / 2 Randomized (as stated in the record)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 3 year(s) since 2025
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Greg Brunson holds only 4 work(s), too few to judge a track record — left out of this score
Institution's track record 0 / 3 Georgetown University Medical Center: institution h-index 564 (OpenAlex)
Multicenter collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41286676)
Free to read — / 2 Access not recorded — left out of this score
Points 46 / 94 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 46 of the 94 points we could judge it on is 49 out of 100.
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — PubMed Central lists this copy as free to read: the link above (checked 10 Oct 2026).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Treatments from nearby years

Also tagged “trial”

783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Treatments

See all studies in Treatments →